Glazer Capital, LLC and Paul J. Glazer Increase Stake in Day One Biopharmaceuticals, Inc.

Glazer Capital, LLC and Paul J. Glazer have collectively acquired a 5.4% ownership stake in Day One Biopharmaceuticals, Inc. (Ticker: DAWN). This filing, a SCHEDULE 13G, indicates that Glazer Capital, as the investment manager for certain Glazer Funds, now beneficially owns 5,615,390 shares of common stock. Paul J. Glazer, as the Managing Member of Glazer Capital, also holds a beneficial ownership interest in these shares. The acquisition occurred on March 12, 2026, with the filing submitted on March 19, 2026. Glazer Capital exercises shared power to vote and dispose of these shares. The filing also includes a certification that the shares were not acquired or held with the purpose or effect of changing or influencing the control of the issuer.